UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Swedish guidelines for device‐aided therapies in Parkinson's disease —Economic evaluation and implementation

Acta neurologica Scandinavica, 2021-08, Vol.144 (2), p.170-178

2021

Volltextzugriff (PDF)

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding

Brain (London, England : 1878), 2006-08, Vol.129 (8), p.2017-2028

2006

Volltextzugriff (PDF)

Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs

Parkinsonism & related disorders, 2016-08, Vol.29, p.17-23

2016

Volltextzugriff (PDF)

A 10-Year Follow-Up of Excessive Daytime Sleepiness in Parkinson’s Disease

Parkinson's disease, 2019, Vol.2019 (2019), p.1-7

2019

Volltextzugriff (PDF)

HMPAO SPECT in Parkinson’s disease (PD) with major depression (MD) before and after antidepressant treatment

Journal of neurology, 2009-09, Vol.256 (9), p.1510-1518

2009

Volltextzugriff (PDF)

Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients

The Journal of clinical investigation, 2015-03, Vol.125 (3), p.1339-1346

2015

Volltextzugriff (PDF)

Does l-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease?

Acta neurologica Scandinavica, 2005-01, Vol.111 (1), p.12-20

2005

Volltextzugriff (PDF)

Oxysterols and Parkinson's disease: Evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease

Neuroscience letters, 2013-10, Vol.555, p.102-105

2013

Volltextzugriff (PDF)

Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder

Frontiers in psychiatry, 2017-06, Vol.8, p.102-102

2017

Volltextzugriff (PDF)

Associations Between Fluctuations in Daytime Sleepiness and Motor and Non‐Motor Symptoms in Parkinson's Disease

Movement disorders clinical practice (Hoboken, N.J.), 2021-01, Vol.8 (1), p.44-50

2021

Volltextzugriff (PDF)

Validity and Responsiveness of At-Home Touch Screen Assessments in Advanced Parkinson's Disease

IEEE journal of biomedical and health informatics, 2015-11, Vol.19 (6), p.1829-1834

2015

Volltextzugriff (PDF)

Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression

Journal of neurology, 2010-04, Vol.257 (4), p.524-532

2010

Volltextzugriff (PDF)

Use of Selegiline as Monotherapy and in Combination with Levodopa in the Management of Parkinson's Disease: Perspectives from the MONOCOMB Study

Progress in neurotherapeutics and neuropsychopharmacology, 2008-03, Vol.3 (1)

2008

Volltextzugriff (PDF)

Workforce unavailability in Parkinson's disease

Acta neurologica Scandinavica, 2017-03, Vol.135 (3), p.332-338

2017

Volltextzugriff (PDF)

A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion

Clinical neuropharmacology, 2011-03, Vol.34 (2), p.61-65

2011

Volltextzugriff (PDF)

A Swedish version of the 16-item Parkinson fatigue scale (PFS-16)

Acta neurologica Scandinavica, 2012-04, Vol.125 (4), p.288-292

2012

Volltextzugriff (PDF)

Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy

Epilepsy research, 2001-02, Vol.43 (2), p.115-124

2001

Volltextzugriff (PDF)

Factors of importance for weight loss in elderly patients with Parkinson's disease

Acta neurologica Scandinavica, 2004-09, Vol.110 (3), p.180-187

2004

Volltextzugriff (PDF)

A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel-Based Morphometry

Journal of neuroimaging, 2012-01, Vol.22 (1), p.28-32

2012

Volltextzugriff (PDF)

The influence of preanalytical conditions on the DJ-1 concentration in human cerebrospinal fluid

Biomarkers in medicine, 2014-03, Vol.8 (3), p.387-394

2014

Volltextzugriff (PDF)

Selegiline delays the onset of disability in de novo parkinsonian patients

Neurology, 1998-08, Vol.51 (2), p.520-525

1998

Volltextzugriff (PDF)

12-month results from a novel test battery used in a duodenal levodopa infusion trial

European journal of neurology, 2010, Vol.17 (s3), p.21

2010

Volltextzugriff (PDF)

Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease

Parkinsonism & related disorders, 2006-12, Vol.12 (8), p.509-513

2006

Volltextzugriff (PDF)

Parkinson's Disease and Depression: Clinical and Neurobiological Studies

Pålhagen, Sven E

2009

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(29)
Dissertationen
(1)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Swedish guidelines for device‐aided therapies in Parkinson's disease —Economic evaluation and implementation

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding

Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs

A 10-Year Follow-Up of Excessive Daytime Sleepiness in Parkinson’s Disease

HMPAO SPECT in Parkinson’s disease (PD) with major depression (MD) before and after antidepressant treatment

Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients

Does l-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease?

Oxysterols and Parkinson's disease: Evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease

Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder

Associations Between Fluctuations in Daytime Sleepiness and Motor and Non‐Motor Symptoms in Parkinson's Disease

Validity and Responsiveness of At-Home Touch Screen Assessments in Advanced Parkinson's Disease

Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression

Use of Selegiline as Monotherapy and in Combination with Levodopa in the Management of Parkinson's Disease: Perspectives from the MONOCOMB Study

Workforce unavailability in Parkinson's disease

A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion

A Swedish version of the 16-item Parkinson fatigue scale (PFS-16)

Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy

Factors of importance for weight loss in elderly patients with Parkinson's disease

A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel-Based Morphometry

The influence of preanalytical conditions on the DJ-1 concentration in human cerebrospinal fluid

EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease

Selegiline delays the onset of disability in de novo parkinsonian patients

12-month results from a novel test battery used in a duodenal levodopa infusion trial

Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease

Parkinson's Disease and Depression: Clinical and Neurobiological Studies

Suchergebnisse filtern